Key result
Dysfunction of BMPR2 and related genes leads to an adverse response of the pulmonary circulation to injury, causing progressive elevation in pulmonary arterial pressure and right heart failure.
Dysfunction of BMPR2 and related genes leads to an adverse response of the pulmonary circulation to injury, suggesting the BMPR2 pathway as a potential therapeutic target for pulmonary hypertension.
BMPR2 pathway merits exploration as a therapeutic target in pulmonary hypertension; hypothesis-generating and requires prospective trials before any clinical adoption.
Knowing that a mutation in the bone mor-phogenetic protein receptor type 2 (BMPR2) gene is present in most patients with a hereditary form of pulmonary hy-pertension (PH) has allowed us to propose therapies that might be of value in patients with all forms of PH.1,2 The premise is based on evidence from cultured cells and experimental animals. Taken together, these studies indicate that dysfunction of BMPR2 and related genes leads to an adverse response of the pulmonary cir-culation to injury, and that this can cause the progressive elevation in pulmonary arterial (PA) pressure and right heart fail-
No takes yet. Share an insight, caveat, or question.
Marlene Rabinovitch (2012) conducted an editorial in Pulmonary hypertension. BMPR2 pathway therapies was evaluated. Dysfunction of BMPR2 and related genes leads to an adverse response of the pulmonary circulation to injury, causing progressive elevation in pulmonary arterial pressure and right heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: